Hazard alert – risk of breast implant-associated anaplastic large cell lymphoma in rare cases
Therapeutic Goods Administration (TGA)
Australian Government Department of Health
Main menu
- Home
- Safety information
- Consumers
- Health professionals
- Industry
- SME Assist
- Basics of therapeutic goods regulation
- Overview of applying for market authorisation
- Medical devices regulation: an introduction
- When to engage with the TGA
- Useful resources for business
- Is my product a therapeutic good?
- What classification is my medical device?
- Which clinical trial scheme should I choose?
- What type of GMP application do I require?
- Training sessions
- What do I require to have a listed medicine in the ARTG?
- Regulation basics
- How therapeutic goods are regulated in Australia
- Australian Register of Therapeutic Goods
- Industry educational materials
- Legislation & legislative instruments
- Advertising hub
- Labelling & packaging
- Exporting therapeutic goods
- Importing therapeutic goods
- Clinical trials
- Cosmetics
- Scientific guidelines
- Safety information for industry
- Prescription medicines
- Over-the-counter medicines
- Complementary medicines
- Sunscreens
- Medical devices & IVDs
- Biologicals
- Blood and blood components
- Other therapeutic goods
- Manufacturing therapeutic goods
- Scheduling of medicines & poisons
- SME Assist
- About the TGA
- News room
